ArticleFrontiers in immunology2025
The diagnostic and prognostic value of CXCL13, CXCL10, and CXCL8 in patients with neurosyphilis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study is to examine the diagnostic and therapeutic value of CXCL13 (CSF-CXCL13), CXCL10 (CSF-CXCL10), and CXCL8 (CSF-CXCXCL8) in NS patients in a systematic manner. Method: The study will include individuals who are the first to undergo neurosyphilis (NS) screening from August 2023 to October 2024, and will gather demographic, clinical, and laboratory data, as well as cerebrospinal fluid (CSF) and blood samples. Enzyme-linked immunosorbent assay (ELISA) was used to quantitatively detect the concentrations of CXCL13, CXCL10, and CXCL8 in CSF and blood samples. Use receiver operating characteristic (ROC) curves to evaluate the ability of cytokines to distinguish between NS and non-NS individuals, and further evaluate in different populations, including the total population, People Living with HIV(PLWH), Non-People Living with HIV(Non-PLWH) population. Develop an NS diagnostic model using logistic regression analysis results, and ensure the model is valid by conducting 5-fold cross-validation, calibration curve, and clinical decision curve (DCA). Use a Nomogram to visualize the model. Result: A total of 233 participants were included in the study. ROC shows that the area under the curve (AUC) of CSF-CXCL13 in distinguishing NS from Non-NS,#x3001; NS from CNS infections is 0.812 and 0.839, respectively. In contrast, the AUC of CSF-CXCL10 and CSF-CXCL8 in distinguishing NS from Non-NS were 0.568 and 0.638, respectively. The AUC in distinguishing NS from other CNS infections were 0.604 and 0.556, respectively. To enhance the effectiveness of differential diagnosis, we employed logistic regression analysis to screen variables and developed a predictive model MODEL1. The results showed that the AUC value of MODEL1 was 0.888, and the calibration curve and DCA curve demonstrated good accuracy and clinical benefits of the model, demonstrating good predictive performance. After NS treatment, the levels of CSF-CXCL13, CSF-CXCL10, and CSF-CXCL8 slightly decreased. Conclusion: CSF-CXCL13 has good differential value in distinguishing NS from Non-NS, NS from CNS infections, while CSF-CXCL10 and CSF-CXCL8 have lower differential sensitivity. The diagnostic performance of the NS diagnostic model (Model 1) based on CSF-CXCL13 has been improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.